Durvalumab Plus Tremelimumab In Patients With Grade 3 Neuroendocrine Neoplasms Of Gastroenteropancreatic Origin: Updated Results From The Multicenter Phase Ii Dune Trial (Getne 1601)
ANNALS OF ONCOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要